Group CEO of CordLife Ltd
Dr. Steven Fang has over two decades of experience in growing life sciences businesses. Dr Fang was the Group CEO of CordLife Ltd, a cord blood banking group based in Singapore. CordLife was founded in May 2001 by Dr Fang, and has since grown to have five cord blood processing and storage facilities, in Singapore, Hong Kong, Jakarta, Indonesia, Kolkata, India, and in Sydney, Australia. The company was listed on the Australian Stock Exchange in 2004, and spun off a separate entity in 2010, which subsequently was listed on the Singapore Stock Exchange. Prior to CordLife, Dr Fang held various management positions in life sciences companies such as Becton Dickinson, Baxter Healthcare and Sterling Pharmaceuticals (now part of GSK).
Senior Fellow, A*STAR
Consultant to ETPL, A*STAR
Adjunct Prof, Duke-NUS CTeD
Prof Steven Myint is a physician with global experience in health and biomedical management. He is actively involved in the commercialization of biomedical and bio-engineering research throughout the world and is serving on the boards of companies from Singapore, Finland, USA and India. Since starting his first spinout in 2005, Prof Myint has been involved in the development of over 30 SME’s in life sciences and created over $1 billion value for shareholders.
Principle Investigator, Mechanobiology Institute
Group Leader, A*STAR
Founding Scientist, HistoIndex Pte Ltd
Dr. Hanry Yu was trained as a cell biologist under the tutorage of Prof. Michael Sheetz at Duke University, USA, and with Gareth Griffiths at EMBL, Germany. In Singapore since 1997, he ventured into Biomaterials, Tissue Engineering, Biophotonics, Computation and Systems Biology, and Mechanobiology; published over 150 high quality papers in these interface areas; filed >40 inventions that result in 3 startups; and delivered >220 invited talks. He consults for international agencies and institutions and takes pride in mentoring over 100 graduate students and staffs who moved onto successful career in academia and industry. He has been a professor of physiology and mechanobiology at the National University of Singapore; group leader at the Institute of Bioengineering and Nanotechnology, A*STAR, visiting professor at MIT, USA since 2008, and a handling editor of Biomaterials.
Founder & Managing Partner, Coffee Ventures
Dr. Eddy Lee has invested in and supported more than 50 startups predominantly in the US, Singapore and Indonesia. Interest areas include mobile health, big data, IoT and marketplaces. He has recently relocated from the Silicon Valley to Southeast Asia to tackle unmet needs in emerging markets. He works with entrepreneurs in product development, enterprise partnership, M&A exit, and entering international markets such as the US, Japan, Singapore and Indonesia. At Stanford University, Eddy concurrently serves as a Consulting Professor at the School of Medicine, where he connects academic projects with commercial opportunities. He is also a mentor at Stanford's StartX incubator where he helps startups in cross border opportunities. During his career at Stanford, Singapore and Australia, he has devised medical imaging technology for visualizing stem cell migration and therapy. He used to design semiconductor chips at Marvell, a NASDAQ-listed Southeast Asia success story which he hopes his portfolio startups could one day emulate.
Carolyn Ng, Ph.D.
Investment Director, Vertex Healthcare Venture Capital
Carolyn Ng is the Investment Director of Vertex Healthcare Ventures, the VC arm of Temasek Holdings specializing in early stage life sciences investments. She is based in the Singapore office, where she evaluates venture investment opportunities across biotechnology and medical devices sectors globally. Prior to joining Vertex, Carolyn was a Consultant at Deallus Consulting, a specialized life sciences strategy consulting firm. While at Deallus, she led multiple consulting projects for large pharmaceutical companies supporting due diligence of in-/out-licensing opportunities, analyzing competitive landscapes of emerging classes of therapeutics, and formulating go-to-market strategies for Asian markets. Carolyn was also a molecular oncology research scientist in YLL School of Medicine, the National University of Singapore. She was a recipient of the NUS Graduate School for Integrative Sciences and Engineering PhD scholarship, and holds the patent of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma.
Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology, and also holds a BS (Pharmacy) (Honours) degree from the National University of Singapore.